JPWO2021207606A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021207606A5
JPWO2021207606A5 JP2022561484A JP2022561484A JPWO2021207606A5 JP WO2021207606 A5 JPWO2021207606 A5 JP WO2021207606A5 JP 2022561484 A JP2022561484 A JP 2022561484A JP 2022561484 A JP2022561484 A JP 2022561484A JP WO2021207606 A5 JPWO2021207606 A5 JP WO2021207606A5
Authority
JP
Japan
Prior art keywords
composition
optionally
cov
sars
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022561484A
Other languages
English (en)
Japanese (ja)
Other versions
JP7840570B2 (ja
JP2023520929A5 (https=
JP2023520929A (ja
Publication date
Priority claimed from US16/875,487 external-priority patent/US11116737B1/en
Application filed filed Critical
Priority claimed from PCT/US2021/026588 external-priority patent/WO2021207606A1/en
Publication of JP2023520929A publication Critical patent/JP2023520929A/ja
Publication of JP2023520929A5 publication Critical patent/JP2023520929A5/ja
Publication of JPWO2021207606A5 publication Critical patent/JPWO2021207606A5/ja
Application granted granted Critical
Publication of JP7840570B2 publication Critical patent/JP7840570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022561484A 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法 Active JP7840570B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063008624P 2020-04-10 2020-04-10
US63/008,624 2020-04-10
US202063023021P 2020-05-11 2020-05-11
US63/023,021 2020-05-11
US16/875,487 2020-05-15
US16/875,487 US11116737B1 (en) 2020-04-10 2020-05-15 Methods of using probenecid for treatment of coronavirus infections
EP20202059.0 2020-10-15
EP20202059.0A EP3892269B1 (en) 2020-04-10 2020-10-15 Probenecid for treating coronavirus infections
US202163151551P 2021-02-19 2021-02-19
US63/151,551 2021-02-19
PCT/US2021/026588 WO2021207606A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Publications (4)

Publication Number Publication Date
JP2023520929A JP2023520929A (ja) 2023-05-22
JP2023520929A5 JP2023520929A5 (https=) 2024-04-16
JPWO2021207606A5 true JPWO2021207606A5 (https=) 2024-04-16
JP7840570B2 JP7840570B2 (ja) 2026-04-06

Family

ID=78023981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561484A Active JP7840570B2 (ja) 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法

Country Status (5)

Country Link
EP (1) EP4132503B1 (https=)
JP (1) JP7840570B2 (https=)
CN (1) CN116075298B (https=)
AU (1) AU2021254262A1 (https=)
WO (1) WO2021207606A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157288A2 (en) * 2020-06-02 2023-04-05 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
JP2024529291A (ja) * 2021-07-06 2024-08-06 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ウイルス感染症の処置および予防のための組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20130280806A1 (en) * 2010-05-17 2013-10-24 Donald Rubin Mammalian genes involved in infection
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN111601618A (zh) * 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
EA202193251A1 (ru) * 2019-06-05 2022-03-10 Эмори Юниверсити Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций

Similar Documents

Publication Publication Date Title
JP2024170583A5 (https=)
US20230201497A1 (en) Method for pulsatile delivery of a gaseous drug
US20220387455A1 (en) Treatment of moderate to severe influenza
CN111658779A (zh) 治疗新型冠状病毒肺炎的联合用药物
JP2020536048A5 (https=)
JPWO2021207606A5 (https=)
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
WO2022199049A1 (zh) 乌司他丁在制备治疗新型冠状病毒肺炎药物中的用途
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
US11497747B2 (en) Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
JPWO2022096708A5 (https=)
CN115884770A (zh) 治疗冠状病毒感染的联用药物及治疗方法
CN115867288A (zh) 用于治疗呼吸系统病症的组合物
KR20250053864A (ko) 호흡기 감염을 치료하기 위한 약제학적 건조 분말 조성물 및 방법
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
BR102020005172A2 (pt) Zinco como medicamento antiviral eficaz para a família coronaviridae e seus genomas, gêneros e grupos
JPWO2023092180A5 (https=)
WO2022145407A1 (ja) Ｄｐ１アンタゴニストおよびノイラミニダーゼ阻害剤からなるウイルス性気道感染症治療用医薬
JPWO2021186151A5 (ja) Ａｚｄ１６５６又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び／又は心筋炎の治療用組成物
JP2021161105A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
JPWO2022258972A5 (https=)
Leigh et al. A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionate
JP2021524858A5 (https=)
Wheatland Corticosteroids are the Best Treatment for COVID-19
JPWO2023067501A5 (https=)